Supercharge your drug redevelopment project
Our Rare Treatment Accelerator (RTA) helps academic, patient, and industry groups advance their rare disease drug redevelopment projects. By combining our team, expertise and financial resources with your research and insights, we can get treatments to patients faster.
Who’s it for?
The RTA is open to all academic, patient and early-stage biotech groups that have a drug redevelopment opportunity for a rare disease. Although different regions have their own definitions of a rare disease, we broadly define it as any condition that affects less than 1 person in 2,000 (5 in 10,000).
We’re particularly keen to hear about projects with strong evidence that the redeveloped drug has therapeutic effects in preclinical disease models and is suitable to move towards human clinical trials.
Why should I apply?
By applying our drug development and clinical expertise, and financial backing, we will help you progress your drug redevelopment project to a clinical trial much faster.